STATCenter·
STAT+: Pharmalittle: We’re reading about an FDA commissioner candidate, Germany’s plans for drug prices, and more
Regenxbio plans to apply for accelerated approval for its gene therapy for Duchenne muscular dystrophy.
Read at STAT →




